Should I Buy ABUS? ABUS 2026 Analysis

Should You Buy Arbutus Biopharma Corp (ABUS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.520

1 Day change

0.44%

52 Week Range

5.100

Analysis Updated At

2026/03/26

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Arbutus Biopharma Corp (ABUS) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available. The stock lacks clear positive momentum, has no significant trading signals, and its financial performance and technical indicators do not suggest an immediate opportunity. Holding off for now is recommended.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 52.824, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 4.378, with resistance at 4.569 and support at 4.187. Overall, the technical indicators suggest no strong directional bias.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Arbutus has strong liquidity with $91.5 million in cash and marketable securities. The company achieved a 128.2% YoY revenue increase in Q4 2025, exceeding market expectations. A settlement with Genevant reduces financial risks, and Moderna faces challenges in its patent dispute with Arbutus.

Neutral/Negative Catalysts

Revenue, net income, and EPS have significantly declined YoY. The technical indicators show no strong upward momentum, and the stock has a high probability of declining in the short term. Analysts note that Arbutus faces challenges in proving patent infringement against Moderna.

Financial Performance

In Q4 2025, revenue dropped by 33.23% YoY to $1.051 million. Net income fell by 70.03% YoY to -$3.756 million, and EPS dropped by 71.43% YoY to -0.02. However, gross margin remained stable at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Jefferies analyst maintains a Buy rating on Arbutus shares, but notes challenges in the patent dispute with Moderna. No recent updates on price target changes.

1 Analyst Rating

Wall Street analysts forecast ABUS stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.500

Low

Averages

High

Current: 4.500

Low

Averages

High

Jefferies

Dennis Ding

Buy

maintain

AI Analysis

2026-02-02

Reason

Jefferies

Dennis Ding

Price Target

AI Analysis

2026-02-02

maintain

Buy

Reason

Jefferies analyst Dennis Ding notes that Judge Wolson issued summary judgment on three matters in a patent fight between Arbutus Biopharma (ABUS) and Moderna (MRNA). While the analyst says two of the three rulings were in-line with the firm's thinking going into summary judgment, the judgement in favor of Moderna that Arbutus cannot claim infringement under the "doctrine of equivalents" seemed "interesting" as the Judge basically is implying Arbutus needs to meet a higher bar to prove infringement. However, this "shouldn't technically change the outcome" since the firm believes Moderna's LNP components lie within Arbutus' patented range, the analyst added. The firm has a Buy rating on Arbutus shares and a Hold rating on Moderna.

ABUS Should I Buy

ABUS Should I Buy

Should You Buy Arbutus Biopharma Corp (ABUS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch